Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs

Executive Summary

The DMD community faces another setback as FDA pushes back timelines for Santhera and its respiratory drug, pushing the market to question what will come for other DMD treatments in development.

Advertisement

Related Content

Santhera Shares Sink On Duchenne Setback in Europe
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales
Inside A Phase III Disappointment: Santhera Reduced Target Population, Now Needs Another Trial
'Surrogate Of A Surrogate' Not Good Enough For Raxone Accelerated Approval
Agony & Ecstasy Of Sarepta: A New FDA Rare Disease Standard?
BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over
FDA Refuses To File Translarna NDA; PTC Plummets
Positive opinion for Santhera's orphan drug Raxone in Europe
Santhera's idebenone hits top-line in Phase III DMD trial

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096900

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel